United States: It's About Time! 10 Key (Needed) Changes Proposed To The Human Subjects Protection "Common Rule"

The world has changed drastically since 1991 when Operation Desert Storm was underway; the USSR crumbled; Prince Charles and Princess Diana separated; the World Wide Web was born; gas cost $1.14; and the Dow peaked at 3168. But until now, the rules and regulations governing human subjects research (the "Common Rule" at 45 C.F.R. Part 46) have not followed suit. On September 8, 2015, 16 federal departments and agencies issued a 519-page Notice of Proposed Rulemaking (NPRM), requesting comments on proposed rules that would update the Common Rule to reduce burden, delay, and ambiguity for clinical research investigators and modernize the research oversight process while still protecting human research subjects.

Below are 10 key (needed) changes to anticipate if the NPRM rules are implemented in their current form (whenever that may be).

1. Redefining "Human Subject" to Include Biospecimens

Three years after publication of the finalized rule, the definition of "Human Subject Research" would change to include biospecimens obtained, used, studied, or analyzed, regardless of whether individually identifiable information about the biospecimen's source may be readily ascertained by the researcher. As a result, most instances of secondary research performed on biospecimens would require informed consent from the patient. If the research is only to generate information about the subject that is already known, such as using the specimen as a control for validation studies, then consent would not be required. When consent would be required for secondary biospecimen research, it could be obtained broadly as described by #2 below. This change is expected to increase subjects' autonomy and control over how their information (including specimens) is used.

Institutional Review Boards (IRBs) would have limited authority to waive the informed consent requirement and would be cautioned never to do so when the research involves biospecimens. Waiver would be permissible when the research could not be carried out practicably without the waiver or alteration because of scientific validity, ethical concerns, or no similar population from which consent can be obtained. Convenience, cost, and speed are to be very minor considerations.

2. Adding Categories of Activities Exempt From Common Rule Oversight

Three broad categories would be established to encompass new exempt activities. These categories vary by the level of documentation, information security, and IRB oversight for the research. These changes are expected to make the IRB review process more efficient for IRBs, administrators, and investigators while still ensuring sufficient safeguards are in place for lower-risk research activities that would not be excluded from Common Rule oversight.

Research that involves low-risk interventions without using any biospecimens or individually identifiable information would simply require documentation of the exemption determination. This may include consumer taste tests, evaluating effectiveness of public benefit programs, or other benign interventions collected through written or verbal responses.

Research that may involve sensitive information would require documentation of the exemption determination and reasonable and appropriate security safeguards (with a checklist to be published at a later date). These research activities may include surveys and interviews recorded with individual identifiers or secondary research using private information where the subject has given consent.

Research involving biospecimens and identifiable information would require documentation of the exemption determination, privacy safeguards, broad consent from the patient, and limited IRB review of the adequacy of the privacy safeguards and process by which broad consent would be sought. Such activities may include storing, maintaining, or using biospecimens or individually identifiable private information for secondary research.

To assist investigators and institutions in making exemption determination decisions, federal departments and agencies would develop exemption determination tools which, if given accurate information, would provide an exemption safe harbor. The government also plans to assist researchers in obtaining broad consent for storing, maintaining, or using biospecimens and individually identifiable private information. The Secretary of the U.S. Department of Health and Human Services (HHS) proposes to develop a broad consent template allowing the subject to consent to future, unspecified research uses of the information or biospecimen.

Of note, if the broad consent template is not used, the exemption would not be available and the consent form would need to be reviewed by the IRB. Additionally, if the researchers plan to return research results to patients, the exemption would not be available.

3. Simplifying Informed Consent Forms

Many consent forms are lengthy tomes filled with complicated legal or medical terminology. The NPRM aims to simplify consent forms, requiring them to list the required elements first, including any HIPAA authorization, with any extraneous information not required by the regulations relegated to an appendix. The consent form would be required to disclose whether individual identifiers will be removed and whether the data will be used for future studies. This may be burdensome on some institutions as there could be a need to develop a system to track limitations of consent and impermissible uses of data.

Additionally, the NPRM poses three new required elements, when applicable: Subjects should (1) be informed when their biospecimens may be used for profit and whether the subject will share in that profit; (2) know if and when clinically relevant results will be disclosed to them; and (3) have the option to consent or refuse future contact by investigators seeking additional information or soliciting additional research studies.

4. Making Consent Forms Publicly Available

Researchers would be required to post on a government website the final version of the informed consent form, including the name of the protocol and relevant contact information, within 60 days after the study is closed to recruitment. This is thought to allow for public scrutiny of the informed consent process.

5. Safeguarding Individually Identifiable Information and Biospecimens

Any research subject to the Common Rule would be required to have reasonable safeguards to protect against security risks or compromising biospecimen integrity. IRBs in possession of individually identifiable information would also be required to implement appropriate safeguards (with a list of acceptable measures to be published at a later date). The NPRM clarifies that if research is already HIPAA-compliant, no additional efforts would be necessary. With creation of a uniform standard, these changes are expected to help ensure that appropriate privacy and confidentiality protections exist without requiring the burden of assigning a committee to review the privacy and confidentiality protections of each study.

6. Using a Single IRB for Cooperative Research

Unless otherwise required by law, all institutions engaged in cooperative research would be required to use a single IRB as the reviewing IRB. Individual institutions would be permitted to continue to use their local IRB, but a single IRB would still be required to oversee the entire study.

Institutions are told not to be concerned about unaffiliated IRBs failing to adhere to Common Rule requirements. Departments and agencies ascribing to the Common Rule would have authority to enforce compliance directly against unaffiliated IRBs that are not operated by an assured institution. Furthermore, institutions would be advised to enter into written agreements with unaffiliated IRBs to establish written procedures to identify the compliance responsibilities of each entity. These changes are expected to streamline the IRB review process for cooperative research studies and give federal agencies and departments a way to hold unaffiliated IRBs accountable for regulatory compliance.

7. Reducing IRBs' Continuing Review Burden

An IRB would no longer be required to continue reviewing studies in the data analysis or clinical follow-up stages unless required by law, provided the IRB receives annual confirmation that the research remains ongoing and no changes have occurred that would require continuing review. Additionally, IRBs would not be required to continue reviewing studies in the third new exemption category that would require limited IRB review at initiation. These reviews are not thought to contribute significantly to human subjects protection yet produce a measurable regulatory burden for researchers.

8. Clarifying "Minimal Risk" Studies Eligible for Expedited IRB Review

To assist IRBs in determining whether a study is of "minimal risk," HHS proposes to publish a list of activities that qualify as minimal risk. This list would be reviewed and updated at least every eight years. IRBs would be required to conduct an expedited review of any activities on the list and document their reasoning and justification when conducting a full review of such activities. This practice is expected to result in consistency between IRBs in making minimal risk determinations.

9. Returning Research Results to Patient Medical Records

The NPRM proposes to encourage IRBs to review an investigator's plan to return individual results to patients' medical records but plans to instruct IRBs not to decide whether such a plan to return those results is needed. Because results may be clinically irrelevant or may cause psychological distress, the NPRM considers this provision an important inclusion in the informed consent process.

10. Expanding Applicability of the Common Rule

If an institution in the United States receives federal support for non-exempt and non-excluded human subjects research, any clinical trial conducted at that institution would be required to be compliant with the Common Rule, regardless of the funding source, unless the research is already subject to FDA oversight. Through implementation of this change, studies posing the most risk to patients would be more likely subject to Common Rule oversight.

The NPRM offers long overdue changes that will benefit from public comment and scrutiny. Please let us know before December 7, 2015 if you would like assistance preparing a comment on the NPRM.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.